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Role of eicosanoids in renal angiotensin II vasoconstriction
during nitric oxide blockade. Nitric oxide (NO) buffers the effect
of vasoconstrictors currently active in the renovascular system.
Enhancement of the angiotensin II (Ang II)-induced vasocon-
striction during NO blockade comprises both AT2-sensitive po-
tentiation, decreasing the half maximal vasoconstriction (EC50)
value to the subnanomolar concentration range, and augmenta-
tion, increasing the maximal effect (Emax) value in the isolated
perfused rat kidney. In this study, we examine whether constric-
tory prostanoids are involved in Ang II subtype receptor (AT2)-
sensitive potentiation of the Ang II effect during NO blockade.
Thus, Ang II-induced vasoconstriction (0.1 or 10 nM Ang II) was
measured in six series of constant-flow perfused isolated rat
kidneys in the presence of indomethacin under control conditions,
during NO inhibition, and during combined inhibition of NO and
all arachidonic pathways by eicosatetraynoic acid (ETYA), an
analog of arachidonic acid. The vasoconstriction elicited by 10 nM
Ang II, which is the maximal response, increased about threefold
during NO inhibition compared with control. This augmentation
was not affected by ETYA. In contrast, the vasoconstriction
elicited by 0.1 nM Ang II increased about 20-fold during NO
inhibition, reflecting mainly potentiation of the Ang II effect. This
increase was abrogated by ETYA. We conclude that vasoconstric-
tor eicosanoids, which are suppressed by endogenous NO, medi-
ate AT2-sensitive potentiation of the Ang II-induced vasoconstric-
tion in the rat kidney.
Angiotensin II (Ang II) is a key factor in the regulation
of renal hemodynamics. Because all components of the
renin-angiotensin system (RAS) are expressed within the
kidney, not only systemically circulating but also locally
generated Ang II controls renovascular tone [1]. Its effects
can be modulated substantially by other paracrine hor-
mones, in particular nitric oxide (NO). Renal NO is
synthesized mainly by the endothelial and the neuronal
NO-synthase (NOS) isoforms localized in vascular endo-
thelium and macula densa [2]. NOS blockade shows clearly
that NO is an important renal vasodilator under control
conditions [3] and can therefore counterbalance a variety of
renal vasoconstrictors [1].
RENAL ANGIOTENSIN II RECEPTORS
Two major Ang II receptor subtypes have been charac-
terized and cloned: AT1 (further subdivided into AT1A and
AT1B) and AT2 [4]. Pharmacologically, AT1 and AT2 can
be distinguished by selective high-affinity receptor antago-
nists: losartan for AT1 and PD-123319 or, in some systems,
CGP-42112A for AT2. Although both receptors possess
seven-transmembrane domains and AT1 signals through
G-protein coupling, signal transduction of the AT2 is
unknown. Despite the presence of AT2 binding sites in
renal vessels [5], their role in regulating renal hemodynam-
ics is unclear, as Ang II-induced vasoconstriction is medi-
ated primarily by AT1 [1]. However, AT2 may participate in
pressure natriuresis [6]. Using a microdialysis technique, it
has been demonstrated recently that AT2 receptors medi-
ate NO accumulation in the renal interstitial fluid [7]
leading to increased cyclic guanosine monophosphate
(cGMP) [8].
NITRIC OXIDE COUNTERACTS THE RENAL
EFFECTS OF VASOCONSTRICTORS
Nitric oxide and vasodilator prostaglandins (PGs) buffer
the renal effects of various vasoconstrictors including Ang
II [1]. Thus, NOS inhibition markedly enhances renal
vasoconstriction in response to Ang II [9, 10]. We have
confirmed recently the effect of NOS inhibition on the Ang
II-induced vasoconstriction in the isolated, constant-flow
perfused rat kidney [11]. NOS inhibition by NG-nitro-L-
arginine methyl ester (L-NAME) augments and potentiates
renal vasoconstriction following Ang II in isolated rat
kidneys perfused in the presence of indomethacin. The
maximal effect (Emax) of Ang II on perfusion pressure in
the isolated kidneys was about three times greater during
NOS inhibition. In addition, the Ang II concentration
inducing half-maximal vasoconstriction (EC50, 0.4 nM) was
about an order of magnitude lower during NOS inhibition,
thereby unmasking strong vasoconstrictor responses to
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physiological (subnanomolar) Ang II concentrations. Use
of either a different NOS inhibitor Nv-nitro-L-arginine or a
soluble guanylyl cyclase inhibitor showed further that the
effects of L-NAME on the Ang II-induced vasoconstriction
were mediated via the NO/cGMP pathway.
MECHANISMS OF NITRIC OXIDE ATTENUATION
OF ANGIOTENSIN II-INDUCED
VASOCONSTRICTION
Both basal and agonist-triggered NO release could at-
tenuate Ang II-induced vasoconstriction. Agonist-triggered
NO release could either be due to an increase in shear
stress or be mediated by endothelial Ang II receptors. The
action of Ang II in isolated renal vessels is attenuated by
the flow-dependent release of endothelial NO [12]. On the
other hand, basal release of NO appears responsible for the
attenuation of the Ang II action, because in the rat kidney,
Ang II vasoconstriction returns to control if the inhibited
amount of endogenous NO is replaced by a fixed amount of
exogenously delivered NO [10, 13]. In the carotid artery,
however, Ang II directly triggers AT1-mediated NO release
from endothelial cells [14]. Similarly, activation of the RAS
during sodium depletion in conscious rats triggers AT2-
mediated NO release into the renal interstitial fluid [7].
This response is mediated partly by neuronal NOS, as it is
blunted by 7-nitroindazole, but other NOS isoforms also
contribute to NO production by this pathway. In summary,
it is unclear whether receptor-mediated release of endo-
thelium-derived NO in response to Ang II operates in the
renal vasculature.
ANGIOTENSIN II-INDUCED VASOCONSTRICTION:
AT2 ANTAGONIST-SENSITIVE POTENTIATION
DURING NITRIC OXIDE BLOCKADE
The sensitivity of Ang II-induced renal vasoconstriction
to AT2 antagonists in the absence of PGs or NOS blockade
had not been addressed specifically until our recent study
on whether the augmentation and potentiation of the Ang
II-induced vasoconstriction during NO inhibition occur via
multiple receptor subtypes [11]. In isolated, constant-flow
perfused kidneys, the AT1 antagonist L-158809 abolished
both potentiated and augmented components of Ang II-
induced vasoconstriction in the presence of both indometh-
acin and L-NAME. Importantly, the AT2 antagonists PD-
123319 and CGP-42112A at concentrations considered to
be subtype selective specifically reversed the L-NAME—
induced left shift of the concentration-response curve, thus
returning EC50 to the value seen in the absence of L-
NAME. PD-123312 also inhibited the Ang II-induced
vasoconstriction potentiated by blockade of cGMP produc-
tion. These studies imply that endogenous NO inhibits
AT2-mediated potentiation of AT1-mediated constriction
in renal vessels.
PROSTANOID INVOLVEMENT IN NITRIC OXIDE-
DEPENDENT AT2-SENSITIVE POTENTIATION OF
ANGIOTENSIN II VASOCONSTRICTION
In addition to the enhancement of vasoconstrictor re-
sponses discussed earlier here, inhibition of NO production
might also enable the release of other endogenous vaso-
constrictors in response to Ang II. For instance, Ang II
stimulates the endothelial release of endothelin-1 [15–17]
and arachidonic acid metabolites [1, 18, 19]. Recently, we
have begun to investigate whether eicosanoids are involved
in the NO-masked AT2-mediated potentiation of AT1-
mediated constrictions in the renal vasculature.
METHODS
Male Wistar rats (170 to 220 g) with free access to
standard food and water were anesthetized by i.p. sodium
pentobarbital (65 mg/kg). The left kidney was isolated and
perfused in an open, nonrecirculating circuit as described
previously [11]. The perfusion solution was an aerated
thermostatted Krebs-Ringer-gelatine-lactate solution
(Plasmion; Rhoˆne-Poulenc Ro¨rer, Antony, France), pH
7.4, containing 10 mM indomethacin. Flow was adjusted in a
60-minute equilibration period to achieve a pressure base-
line of 90 mm Hg and subsequently kept constant. L-
NAME (0.1 mM) or 2 mM 5, 8, 11, 14-eicosatetraynoic acid
(ETYA; Calbiochem, La Jolla, CA, USA) or both were
added to the perfusate as required. After equilibration, 0.1
or 10 nM Ang II was infused over a fixed period of six
minutes. The effect of Ang II on perfusion pressure
increase was expressed as the area under the curve over the
6-minute Ang II infusion. Data are means 6 SEM and are
expressed as mm Hg minute. Analysis of variance and the
Student-Newman-Keul’s test for individual means were
used for data analysis.
RESULTS AND DISCUSSION
Basal renal vascular resistance (RVR, 7.9 6 0.2 mm Hg
min g/ml, N 5 9) increased significantly with L-NAME
(12.1 6 0.6 mm Hg min g/ml, N 5 18) or ETYA (9.8 6 0.9
mm Hg min g/ml, N 5 6). Because ETYA, an arachidonic
acid analog, blocked all pathways of arachidonic acid
metabolism [20], these observations strongly suggest that
not only NO, but also prostanoids, contributes to the basal
state and exerts a net vasodilator effect on the isolated
perfused rat kidney. Among the arachidonic acid metabo-
lites possibly involved, PGs can be excluded because indo-
methacin was present. On the other hand, in the presence
of L-NAME, ETYA did not affect RVR further (RVRL-
NAME 5 12.1 6 0.6 mm Hg min g/ml, N 5 18; RVRETYA 5
11.2 6 0.3 mm Hg min g/ml, N 5 11), indicating that NO
suppresses the contribution of endogenous constrictor pro-
stanoids to basal RVR. Consistent with this view, it has
been shown recently that NO inhibits renal vasoconstrictor
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compounds by blockade of P450 enzymes [21] at the
catalytic heme binding site in these enzymes [22].
We explored the effect of ETYA on vasoconstriction
induced by 0.1 and 10 nM Ang II, concentrations at which
L-NAME potentiates and augments, respectively [11]. L-
NAME consistently augmented the vasoconstriction in-
duced by 0.1 or 10 nM Ang II by 20 and 3.2 times,
respectively (Fig. 1). The new finding is that ETYA virtu-
ally abolishes the L-NAME—potentiated vasoconstriction
induced by 0.1 nM Ang II but has no effect on the
L-NAME—augmented vasoconstriction induced by 10 nM
Ang II (Fig. 1). These findings indicate strongly that
NO-masked, AT2-sensitive vasoconstriction induced by
physiological Ang II levels [11] in rat renal vessels is
mediated by arachidonic acid metabolites. They also
strongly suggest that NO blunts AT2-sensitive Ang II-
induced vasoconstriction by inhibiting the phospholipase
A2 (PLA2)/arachidonic acid pathway. Whether the endo-
thelium is involved is not known. Because cyclooxygenase
was blocked in our studies, arachidonic acid availability for
utilization by other pathways could have been increased
artificially.
Lipoxygenase- or P450-derived compounds are likely to
be involved in this process, as some of these constrict the
renal vasculature [1]. Leukotrienes C4 and D4 are renal
vasoconstrictors [23], and P450 metabolites contribute to
the effect of various vasoconstrictors in the isolated per-
fused rat kidney [24]. The exact nature of eicosanoid
involvement in potentiating Ang II-induced vasoconstric-
tion remains to be determined.
APPENDIX
Abbreviations used in this article are: Ang II, angiotensin II; cGMP,
cyclic guanosine monophosphate; ETYA, eicosatetraynoic acid;
L-NAME, NG-nitro-L-arginine methyl ester; NO, nitric oxide; NOS, nitric
oxide synthase; PGs, prostaglandins; RAS, renin-angiotensin system;
RVR, renal vascular resistance.
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